Arcellx, Inc. ACLX 深 沪
已收盘 02-06 16:00:00 美东时间
68.03
+1.090
+1.63%
华盛通- 最 高68.82
- 今 开67.95
- 成交量 57.52万股
- 最 低 66.44
- 昨 收 66.94
- 总市值 39.34亿
- 52周最高 94.07
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 47.8601
- 委 比 81.47%
- 总股本 5782.29万
- 历史最高 107.3699
- 量 比 0.76
- 振 幅 3.56%
- 历史最低 6.035
- 每 手 1
- 风险率 8.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
Needham Reiterates Buy on Arcellx, Maintains $105 Price Target
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $105 price target.
02-05 19:20
Arcellx Announces Its Late-breaking Abstract For Its Novel For Its D-Domain Binder In Anitocabtagene Autoleucel Accepted For Presentation At 2026 Tandem Meetings
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late-breaking abstract
02-04 22:07
Arcellx Advances Both Its Scientific Foundation For Its D-Domain Platform Technology And Commercial Preparedness For Anito-Cel For The Potential Treatment Of Multiple Myeloma With Three Presentations At The 2026 Tandem Meetings
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, is advancing both its scientific
01-22 05:14
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Assumes Arcellx at Buy, Announces Price Target of $100
UBS analyst Michael Yee assumes Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of $100.
01-08 04:42
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
2025-12-09 02:23
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones falling more than 200 points on Mond...
2025-12-09 01:33
Needham Reiterates Buy on Arcellx, Maintains $105 Price Target
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $105 price target.
2025-12-08 18:39
